Movement Alert｜GenScript Biotech Rises 23.48% in Regular Trading, Legend Biotech In Vivo CAR-T Clinical Data Shows Positive Signals

Market Focus

Jun 03

On June 3, GenScript Biotech surged 23.48% in regular trading, trading at HKD 14.6/share, with trading volume of HKD 156 million.

On the news front, GenScript's associate company Legend Biotech disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy LB2501 in relapsed or refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL) patients, showing positive signals. The data will be presented at the European Hematology Association (EHA) annual meeting to be held in Stockholm, Sweden from June 11 to June 14. By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to cover with traditional CAR-T cell therapies.

This follows closely on the heels of Legend Biotech's ASCO presentations featuring LB2102 first-in-human data targeting DLL3 for solid tumors and updated CARVYKTI data for multiple myeloma. The successive pipeline catalysts, combined with ongoing market discussion around GenScript's valuation discount relative to its Legend Biotech stake, have collectively driven strong upward momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1124522351"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124522351\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124522351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124522351","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GenScript Biotech Rises 23.48% in Regular Trading, Legend Biotech In Vivo CAR-T Clinical Data Shows Positive Signals","media":"Market Focus","content":"<p><p>On June 3, GenScript Biotech surged 23.48% in regular trading, trading at HKD 14.6/share, with trading volume of HKD 156 million.</p><p>On the news front, GenScript's associate company Legend Biotech disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy LB2501 in relapsed or refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL) patients, showing positive signals. The data will be presented at the European Hematology Association (EHA) annual meeting to be held in Stockholm, Sweden from June 11 to June 14. By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to cover with traditional CAR-T cell therapies.</p><p>This follows closely on the heels of Legend Biotech's ASCO presentations featuring LB2102 first-in-human data targeting DLL3 for solid tumors and updated CARVYKTI data for multiple myeloma. The successive pipeline catalysts, combined with ongoing market discussion around GenScript's valuation discount relative to its Legend Biotech stake, have collectively driven strong upward momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GenScript Biotech Rises 23.48% in Regular Trading, Legend Biotech In Vivo CAR-T Clinical Data Shows Positive Signals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GenScript Biotech Rises 23.48% in Regular Trading, Legend Biotech In Vivo CAR-T Clinical Data Shows Positive Signals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, GenScript Biotech surged 23.48% in regular trading, trading at HKD 14.6/share, with trading volume of HKD 156 million.</p><p>On the news front, GenScript's associate company Legend Biotech disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy LB2501 in relapsed or refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL) patients, showing positive signals. The data will be presented at the European Hematology Association (EHA) annual meeting to be held in Stockholm, Sweden from June 11 to June 14. By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to cover with traditional CAR-T cell therapies.</p><p>This follows closely on the heels of Legend Biotech's ASCO presentations featuring LB2102 first-in-human data targeting DLL3 for solid tumors and updated CARVYKTI data for multiple myeloma. The successive pipeline catalysts, combined with ongoing market discussion around GenScript's valuation discount relative to its Legend Biotech stake, have collectively driven strong upward momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1124522351","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124522351","pubTimestamp":1780450396,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, GenScript Biotech surged 23.48% in regular trading, trading at HKD 14.6/share, with trading volume of HKD 156 million.On the news front, GenScript's associate company Legend Biotech...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"动感快讯|金斯瑞生物常规交易涨23.48%传奇生物体内CAR-T临床数据显示积极信号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On June 3, GenScript Biotech surged 23.48% in regular trading, trading at HKD 14.6/share, with trading volume of HKD 156 million.On the news front, GenScript's associate company Legend Biotech disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy LB2501 in relapsed or refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL) patients, showing positive signals. The data will be presented at the European Hematology Association (EHA) annual meeting to be held in Stockholm, Sweden from June 11 to June 14. By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to cover with traditional CAR-T cell therapies.This follows closely on the heels of Legend Biotech's ASCO presentations featuring LB2102 first-in-human data targeting DLL3 for solid tumors and updated CARVYKTI data for multiple myeloma. The successive pipeline catalysts, combined with ongoing market discussion around GenScript's valuation discount relative to its Legend Biotech stake, have collectively driven strong upward momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}